Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 55.35% is 14% above its 5-year average of 48.62%, near the high end of its 5-year range (-145.50%–86.30%).
566.53% above its 12-month average of -11.86%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 35.86%.
GROSS MARGIN
55.35%
GROSS MARGIN AVG TTM
-11.86%
GROSS MARGIN AVG 3Y
30.19%
GROSS MARGIN AVG 5Y
48.62%
GROSS MARGIN AVG 10Y
57.51%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+566.53%
CURRENT VS 3Y AVG
+83.32%
CURRENT VS 5Y AVG
+13.84%
CURRENT VS 10Y AVG
-3.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.99%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-6.18%
vs the sector median at left
Market Cap
$49.62B
Gross Margin
77.98%
TTM Avg
78.79%
3Y Avg
78.80%
5Y Avg
77.78%
Market Cap
$49.54B
Gross Margin
46.12%
TTM Avg
45.33%
3Y Avg
44.44%
5Y Avg
44.19%
Market Cap
$42.92B
Gross Margin
52.47%
TTM Avg
50.27%
3Y Avg
48.88%
5Y Avg
48.29%
Market Cap
$42.30B
Gross Margin
26.23%
TTM Avg
30.59%
3Y Avg
32.75%
5Y Avg
33.07%
Market Cap
$40.89B
Gross Margin
53.73%
TTM Avg
53.36%
3Y Avg
52.95%
5Y Avg
53.14%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $53.81B | 55.35% | -11.86% | 30.19% | 48.62% |
| Cardinal Health, Inc. (CAH)vs › | $56.21B | 3.84% | 3.75% | 3.54% | 3.65% |
| Edwards Lifesciences Corporation (EW)vs › | $49.62B | 77.98% | 78.79% | 78.80% | 77.78% |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | 46.12% | 45.33% | 44.44% | 44.19% |
| Humana Inc. (HUM)vs › | $48.03B | 13.65% | 14.54% | 16.14% | 17.03% |
| Cencora, Inc. (COR)vs › | $62.91B | 3.71% | 3.06% | 3.07% | 2.95% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | 52.47% | 50.27% | 48.88% | 48.29% |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | 26.23% | 30.59% | 32.75% | 33.07% |
| Agilent Technologies, Inc. (A)vs › | $40.89B | 53.73% | 53.36% | 52.95% | 53.14% |
| Boston Scientific Corporation (BSX)vs › | $66.83B | 71.16% | 65.16% | 63.29% | 62.03% |
Gross Margin
55.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 35.86% |
| 2026-03-31 | -145.50% |
| 2025-12-31 | 33.33% |
| 2025-09-30 | 0.79% |
| 2025-06-30 | 16.20% |
| 2025-03-31 | 15.89% |
| 2024-12-31 | 22.70% |
| 2024-09-30 | 72.29% |
| 2024-06-30 | 47.96% |
| 2024-03-31 | 42.51% |
| 2023-12-31 | 66.97% |
| 2023-09-30 | -22.39% |
| 2023-06-30 | -112.50% |
| 2023-03-31 | 56.91% |
| 2022-12-31 | 62.75% |
| 2022-09-30 | 65.84% |
| 2022-06-30 | 69.75% |
| 2022-03-31 | 82.88% |
| 2021-12-31 | 86.30% |
| 2021-09-30 | 85.05% |
| 2021-06-30 | 82.21% |
| 2021-03-31 | 88.93% |
| 2020-12-31 | 97.26% |
| 2020-09-30 | 94.62% |
| 2020-06-30 | 88.55% |
| 2020-03-31 | 11.21% |
| 2019-12-31 | 36.40% |
| 2019-09-30 | 57.17% |
| 2019-06-30 | 42.67% |
| 2019-03-31 | 54.35% |
| 2018-12-31 | 79.25% |
| 2018-09-30 | 84.48% |
| 2018-06-30 | -262.13% |
| 2018-03-31 | -210.36% |
| 2017-12-31 | 93.56% |
| 2017-09-30 | 87.92% |
| 2017-06-30 | -178.55% |
| 2017-03-31 | -178.55% |
